Navigation Links
AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008
Date:2/10/2009

Patients filled 2.7 million prescriptions through AZ&Me(TM) Prescription Savings Programs

WILMINGTON, Del., Feb. 10 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it provided $612.6 million in savings to 440,541 patients in the United States last year through its AZ&Me(TM) Prescription Savings programs.

Patients filled 2.7 million prescriptions through the programs in 2008.

"AstraZeneca is committed to helping patients who are facing health and financial challenges," said Rich Fante, President of AstraZeneca US. "Our prescription savings programs provide support for patients who might otherwise go without the medicines they need."

AstraZeneca provides free or low-cost medicines to patients through its AZ&Me(TM) Prescription Savings programs in three ways:

  • Individuals: AstraZeneca provides free medicines to qualifying individuals without prescription drug coverage who make up to $30,000 per year and families of four with $60,000 annual household income.

  • Part D beneficiaries: AstraZeneca provides low-cost medicines for qualifying Medicare Part D patients who make up to $30,000 per year or couples who make up to $40,000 per year.

  • Healthcare facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program connects patients to the medicines they need at the same time and place they receive their treatment.

AstraZeneca has offered prescription savings programs side by side with its medicines for three decades and offers one of the industry's most generous programs.

In 2009, AstraZeneca will continue to reach patients who need help through a variety of channels, including community health centers, our product advertisements, and health care professionals and advocates, who are the leading source of information about our programs, according to an AstraZeneca survey. The company also participates in the Partnership for Prescription Assistance, a multi-company program.

Patients can learn more about the AZ&Me Prescription Savings program at www.azandme.com or by calling 1-800-AZandMe.

A podcast related to this news release can be found here.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.35 billion dollar healthcare business with 12,200 employees committed to improving people's lives. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information visit http://www.astrazeneca-us.com./


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
2. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
3. AstraZenecas Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
4. AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva
5. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
6. AstraZenecas Purplepill.com Tops the List of Most Visited Pharmaceutical Brand Web Sites in Q2 2008
7. AstraZeneca Recognized as One of Working Mother Magazines 100 Best Companies
8. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
9. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
10. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
11. A Drug That Carries a Lower Risk of Weight Gain Than AstraZenecas Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: